Reviews Laronidase


No reviews yet.

Aldurazyme Drug Description
ALDURAZYME®
(laronidase) Solution for Intravenous Infusion Only

WARNING
Risk of anaphylaxis.
Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

DRUG DESCRIPTION



What are the possible side effects of laronidase (Aldurazyme)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Some people receiving a laronidase injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you have a headache, skin rash or itching, warmth or tingly feeling, or trouble breathing when laronidase is injected.
Less serious side effects may include:

runny...
Read All Potential Side Effects for Aldurazyme »




ALDURAZYME® (laronidase) is a polymorphic variant of the human enzyme, α-L-iduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. α-L-iduronidase (glycosaminoglycan α-L-iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate.
Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human α-L-iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus and contains 6 N-linked oligosaccharide modification sites. Two oligosaccharide chains terminate in mannose-6-phosphate sugars. ALDURAZYME has a specific activity of approximately 172 U/mg.
ALDURAZYME, for intravenous infusion, is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP, containing 0.1% Albumin (Human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg laronidase, 43.9 mg sodium chloride, 63.5 mg sodium phosphate monobasic monohydrate, 10.7 mg sodium phosphate dibasic heptahydrate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use only.Last reviewed on RxList: 2/4/2009




Aldurazyme Drug Description
ALDURAZYME®
(laronidase) Solution for Intravenous Infusion Only

WARNING
Risk of anaphylaxis.
Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

DRUG DESCRIPTION



What are the possible side effects of laronidase (Aldurazyme)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Some people receiving a laronidase injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you have a headache, skin rash or itching, warmth or tingly feeling, or trouble breathing when laronidase is injected.
Less serious side effects may include:

runny...
Read All Potential Side Effects for Aldurazyme »




ALDURAZYME® (laronidase) is a polymorphic variant of the human enzyme, α-L-iduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. α-L-iduronidase (glycosaminoglycan α-L-iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate.
Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human α-L-iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus and contains 6 N-linked oligosaccharide modification sites. Two oligosaccharide chains terminate in mannose-6-phosphate sugars. ALDURAZYME has a specific activity of approximately 172 U/mg.
ALDURAZYME, for intravenous infusion, is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP, containing 0.1% Albumin (Human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg laronidase, 43.9 mg sodium chloride, 63.5 mg sodium phosphate monobasic monohydrate, 10.7 mg sodium phosphate dibasic heptahydrate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use only.Last reviewed on RxList: 2/4/2009




Aldurazyme Drug Description
ALDURAZYME®
(laronidase) Solution for Intravenous Infusion Only

WARNING
Risk of anaphylaxis.
Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

DRUG DESCRIPTION



What are the possible side effects of laronidase (Aldurazyme)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Some people receiving a laronidase injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you have a headache, skin rash or itching, warmth or tingly feeling, or trouble breathing when laronidase is injected.
Less serious side effects may include:

runny...
Read All Potential Side Effects for Aldurazyme »




ALDURAZYME® (laronidase) is a polymorphic variant of the human enzyme, α-L-iduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. α-L-iduronidase (glycosaminoglycan α-L-iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate.
Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human α-L-iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus and contains 6 N-linked oligosaccharide modification sites. Two oligosaccharide chains terminate in mannose-6-phosphate sugars. ALDURAZYME has a specific activity of approximately 172 U/mg.
ALDURAZYME, for intravenous infusion, is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP, containing 0.1% Albumin (Human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg laronidase, 43.9 mg sodium chloride, 63.5 mg sodium phosphate monobasic monohydrate, 10.7 mg sodium phosphate dibasic heptahydrate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use only.Last reviewed on RxList: 2/4/2009




Aldurazyme Drug Description
ALDURAZYME®
(laronidase) Solution for Intravenous Infusion Only

WARNING
Risk of anaphylaxis.
Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

DRUG DESCRIPTION



What are the possible side effects of laronidase (Aldurazyme)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Some people receiving a laronidase injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you have a headache, skin rash or itching, warmth or tingly feeling, or trouble breathing when laronidase is injected.
Less serious side effects may include:

runny...
Read All Potential Side Effects for Aldurazyme »




ALDURAZYME® (laronidase) is a polymorphic variant of the human enzyme, α-L-iduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. α-L-iduronidase (glycosaminoglycan α-L-iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate.
Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human α-L-iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus and contains 6 N-linked oligosaccharide modification sites. Two oligosaccharide chains terminate in mannose-6-phosphate sugars. ALDURAZYME has a specific activity of approximately 172 U/mg.
ALDURAZYME, for intravenous infusion, is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP, containing 0.1% Albumin (Human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg laronidase, 43.9 mg sodium chloride, 63.5 mg sodium phosphate monobasic monohydrate, 10.7 mg sodium phosphate dibasic heptahydrate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use only.Last reviewed on RxList: 2/4/2009




Aldurazyme Drug Description
ALDURAZYME®
(laronidase) Solution for Intravenous Infusion Only

WARNING
Risk of anaphylaxis.
Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

DRUG DESCRIPTION



What are the possible side effects of laronidase (Aldurazyme)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Some people receiving a laronidase injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you have a headache, skin rash or itching, warmth or tingly feeling, or trouble breathing when laronidase is injected.
Less serious side effects may include:

runny...
Read All Potential Side Effects for Aldurazyme »




ALDURAZYME® (laronidase) is a polymorphic variant of the human enzyme, α-L-iduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. α-L-iduronidase (glycosaminoglycan α-L-iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate.
Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human α-L-iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus and contains 6 N-linked oligosaccharide modification sites. Two oligosaccharide chains terminate in mannose-6-phosphate sugars. ALDURAZYME has a specific activity of approximately 172 U/mg.
ALDURAZYME, for intravenous infusion, is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP, containing 0.1% Albumin (Human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg laronidase, 43.9 mg sodium chloride, 63.5 mg sodium phosphate monobasic monohydrate, 10.7 mg sodium phosphate dibasic heptahydrate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use only.Last reviewed on RxList: 2/4/2009





Other reviews about Laronidase on wordpress

Scottish Area Health Boards - not a place of transparency or fairness as patients made to fight for treatment
  by petercherbi
 No lawyers today - something much worse. Making people fight for three years to get medical treatment for their child. Is this a good advertisement for New Labour & […]


After Hours
  by misstrade
7:28 CASB Cascade Bancorp pre-announced an expected Q4 2007 provision for credit losses of $7.5 mln (Pre-Tax) with resulting net income for the quarter and FY estimated […]


Drug Information Update- Information for Healthcare Professionals - Potential Contamination of Products Manufactured by Genzyme Corporation
  by neurologist
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation byFDA. FDA […]



Other reviews about Laronidase on web:

Approximately 91% of patients treated with ALDURAZYME in clinical studies were positive for antibodies to laronidase. The clinical significance of antibodies to ALDURAZYME is ... Aldurazyme.com | Mucopolysaccharidosis I (MPSI) Treatment Information


All about Laronidase. View complete and up to date Laronidase information - part of the Drugs.com trusted medication database. Laronidase Facts and Comparisons at Drugs.com


Mayo Clinic offers award-winning medical and health information and tools for healthy living. Laronidase (Intravenous Route) - MayoClinic.com


Learn about the prescription medication Aldurazyme (Laronidase), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Aldurazyme (Laronidase) Drug Information: Uses, Side Effects, Drug ...


(Redirected from Laronidase) ... Iduronidase is an enzyme involved in the degeneration of glycosaminoglycans such as ... Iduronidase - Wikipedia, the free encyclopedia


Physician reviewed laronidase patient information - includes laronidase description, dosage and directions. laronidase medical facts from Drugs.com


Laronidase is a prescription medication that is used to treat an enzyme deficiency in patients who suffer from some forms of MPS I|mucopolysaccharidosis I such as Hurler Syndrome ... Laronidase - OrganizedWisdom Health


Laronidase injection To return to the main entry click here . What is laronidase injection? LARONIDASE (Aldurazyme®) is a drug that replaces an Laronidase injection: Information from Answers.com


laronidase, a rarely used miscellaneous drug. indication This drug is used to treat mucopolysaccharidosis I. contraindication Known hypersensitivity to this drug prohibits its use. laronidase - definition of laronidase in the Medical dictionary ...


B lueCross BlueShield of Tennessee Medical Policy Manual. Laronidase. DESCRIPTION. Laronidase is a biosynthetic (recombinant DNA origin) form of L-iduronidase (alpha-L-iduronidase ... Laronidase





Featured Reviews

Reviews Vivactil

Vivactil Drug Description VIVACTIL (protriptyline hydrochloride) Tablet, Film Coated Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in...
Read More  |  Review This
Reviews Midamor

Midamor Drug Description Midamor (amiloride HCl) DRUG DESCRIPTION What are the possible side effects of amiloride (Midamor)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing;...
Read More  |  Review This
Reviews Natrecor

Natrecor Drug Description NATRECOR® (nesiritide) DRUG DESCRIPTION What are the possible side effects of nesiritide (Natrecor)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Diprolene AF

Diprolene AF Drug Description DIPROLENE® AF (augmented betamethasone dipropionate)* Cream 0.05% (potency expressed as betamethasone) *Vehicle augments the penetration of the steroid. For Dermatologic Use Only - Not for Ophthalmic...
Read More  |  Review This
Reviews Foscarnet Sodium Injection

Foscavir Drug Description FOSCAVIR® (foscarnet sodium) Injection WARNING RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCAVIR. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....